Novel benzoxazole inhibitors of mPGES-1

被引：25

作者：

Kablaoui, Natasha ^{[1
]}

Patel, Snahel ^{[2
]}

Shao, Jay ^{[1
]}

Demian, Douglas ^{[3
]}

Hoffmaster, Keith ^{[4
]}

Berlioz, Francioise ^{[5
]}

Vazquez, Michael L. ^{[6
]}

Moore, William M. ^{[7
]}

Nugent, Richard A. ^{[1
]}

机构：

[1] Pfizer Res Technol Ctr, Cambridge, MA 02139 USA

[2] Genentech Inc, San Francisco, CA 94080 USA

[3] Blue Sky Biotech Inc, Worcester, MA 01605 USA

[4] Novartis Inc, Cambridge, MA 02139 USA

[5] Vertex, Cambridge, MA 02139 USA

[6] Pfizer Global Res, Groton, CT 06340 USA

[7] Monsanto Co, St Louis, MO 63167 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 03期

关键词：

mPGES-1; Benzoxazole; Selective; PROSTAGLANDIN-E SYNTHASE-1; EXPRESSION; ARTHRITIS; CARTILAGE; PYRESIS;

D O I：

10.1016/j.bmcl.2012.10.040

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of potent benzoxazole mPGES-1 inhibitors has been derived from a hit from a high throughput screen. Compound 37 displays mPGES-1 inhibition in an enzyme assay (0.018 mu M) and PGE-2 inhibition in a cell-based assay (0.034 mu M). It demonstrates 500- and 2500-fold selectivity for mPGES-1 over COX-2 and 6-keto PGF-1 alpha, respectively. In vivo PK studies in dogs demonstrate 55% oral bioavailability and an 7 h half-life. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：907 / 911

页数：5

共 50 条

[1] Computational design, synthesis and characterization of novel mPGES-1 inhibitors
Zhou, Ziyuan
Ding, Kai
Zhou, Shuo
Yuan, Yaxia
Zheng, Fang
Zhan, Chang-Guo
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[2] MPGES-1 as a novel target for arthritis
Fahmi, H
CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (05) : 623 - 627
[3] mPGES-1 inhibitors from start to clinic
Schiffler, Matthew
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[4] Identification of novel mPGES-1 inhibitors through screening of a chemical library
Park, Sung-Jun
Han, Seong-Gu
Ahsan, Hafiz Muhammad
Lee, Kijae
Lee, Jae Yeol
Shin, Ji-Sun
Lee, Kyung-Tae
Kang, Nam-Suk
Yu, Yeon Gyu
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (24) : 7335 - 7339
[5] Synthesis and SAR study of imidazoquinolines as a novel structural class of mPGES-1 inhibitors
Shiro, Tomoya
Nagata, Hidetaka
Kakiguchi, Keisuke
Inoue, Yoshifumi
Masuda, Keiki
Tobe, Masanori
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[6] Trisubstituted ureas as potent and selective mPGES-1 inhibitors
Chiasson, Jean-Francois
Boulet, Louise
Brideau, Christine
Chau, Anh
Claveau, David
Cote, Bernard
Ethier, Diane
Giroux, Andre
Guay, Jocelyne
Guiral, Sebastien
Mancini, Joseph
Masse, Frederic
Methot, Nathalie
Riendeau, Denis
Roy, Patrick
Rubin, Joel
Xu, Daigen
Yu, Hongping
Ducharme, Yves
Friesen, Richard W.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1488 - 1492
[7] Identification and development of mPGES-1 inhibitors: where we are at?
Chang, Hui-Hua
Meuillet, Emmanuelle J.
FUTURE MEDICINAL CHEMISTRY, 2011, 3 (15) : 1909 - 1934
[8] Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors
Xia, Zhonghua
Yan, Aixia
MOLECULAR DIVERSITY, 2017, 21 (03) : 661 - 675
[9] Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors
Zhonghua Xia
Aixia Yan
Molecular Diversity, 2017, 21 : 661 - 675
[10] mPGES-1 deletion increases prostacyclin and evades the elevated systemic ADMA associatedwith COX-2 inhibitors: relevance to cardiovascular safety of mPGES-1 inhibitors
Raouf, J.
Kirkby, N.
Ahmetaj-Shala, B.
Liu, B.
MRes, S. M.
Korotkova, M.
Zeldin, D.
Zhou, Y.
Jakobsson, P-J
Mitchell, J.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 24 - 25

← 1 2 3 4 5 →